Corrigendum to "Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy" [Heliyon 4 (12) (December 2018) e01039]
Heliyon
.
2019 Mar 18;5(3):e01309.
doi: 10.1016/j.heliyon.2019.e01309.
eCollection 2019 Mar.
Authors
Xiaosheng Wu
1
,
Yanli Li
2
,
Xin Liu
2
,
Chunhua Chen
3
,
Susan M Harrington
2
,
Siyu Cao
2
,
Tiancheng Xie
2
,
Tu Pham
4
,
Aaron S Mansfield
5
,
Yiyi Yan
5
,
Eugene D Kwon
2
4
,
Liewei Wang
6
,
Kun Ling
3
,
Haidong Dong
2
4
Affiliations
1
Department of Medicine Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN, USA.
2
Department of Urology, Mayo Clinic College of Medicine, Rochester, MN, USA.
3
Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN, USA.
4
Department of Immunology, Mayo Clinic College of Medicine, Rochester, MN, USA.
5
Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA.
6
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN, USA.
PMID:
30937406
PMCID:
PMC6426698
DOI:
10.1016/j.heliyon.2019.e01309
Abstract
[This corrects the article DOI: 10.1016/j.heliyon.2018.e01039.].
Publication types
Published Erratum